Conor Medsystems, Inc. was acquired by Johnson & Johnson in January 2007. Prior to the acquisition, Conor was developing, manufacturing and marketing next generation drug eluting stents. The company's initial focus was on the treatment of coronary restenosis. Conor completed an IPO in December 2004.